Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling
5 November 2014
Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines? In September 2014 the Centre for Innovation in Regulatory Science held a workshop…
OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
29 October 2014
ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. This is the second of two blog posts that outlines OHE’s involvement. (The…
OHE at ISPOR Europe 1: Impact of NICE on Innovation and Value
22 October 2014
ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. OHE’s Adrian Towse is current President of ISPOR and involved in several sessions.…
Towse at ISPOR: Macro HTA and Managed Entry Agreements
7 October 2014
Adrian Towse, currently President of ISPOR, contributed to two session at the recent ISPOR Asia-Pacific conference. Using HTA to maximise health system performance: Health technology assessment…
Bengt Jönsson Honoured for Contribution to Health Economics
6 August 2014
Launched at a seminar in his honour May 2014, Portrait of a Health Economist: Essays by Colleagues and Friends of Bengt Jönsson is an impressive collection…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
OHE’s active involvement in a number of recent conferences and meetings has contributed to discussions on a range of important issue in health economics.
Implementing NICE Decisions in Wales: Opportunity Costs
10 June 2014
Just out is a new Research Paper from OHE that examines how local NHS organisations in Wales adjust spending to accommodate ‘shocks’ such as new NICE…
OHE’s Adrian Towse to Take Office as ISPOR President
3 June 2014
The challenge of globalisation heads Towse’s list of four core targets for ISPOR. OHE’s Director, Adrian Towse, is President of the International Society for Pharmacoeconomics and…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
Towse and Drummond take a critical look at deficiencies in policy and suggest revisions. An editorial just published by OHE’s Adrian Towse and Michael Drummond of…